Institut Català de la Salut
[Protasoni M] Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. Cambridge Institute of Science, Altos Labs, Granta Park, Cambridge, UK. [López-Polo V, Attolini CSO] Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. [Brandariz J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Herranz N] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Mateo J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-01-28T13:02:26Z
2025-01-28T13:02:26Z
2024-12-02
Senescencia celular; Ciclofilina D; Mitocondrias
Senescència cel·lular; Ciclofilina D; Mitocondris
Cellular senescence; Cyclophilin D; Mitochondria
Senescent cells play a causative role in many diseases, and their elimination is a promising therapeutic strategy. Here, through a genome-wide CRISPR/Cas9 screen, we identify the gene PPIF, encoding the mitochondrial protein cyclophilin D (CypD), as a novel senolytic target. Cyclophilin D promotes the transient opening of the mitochondrial permeability transition pore (mPTP), which serves as a failsafe mechanism for calcium efflux. We show that senescent cells exhibit a high frequency of transient CypD/mPTP opening events, known as 'flickering'. Inhibition of CypD using genetic or pharmacologic tools, including cyclosporin A, leads to the toxic accumulation of mitochondrial Ca2+ and the death of senescent cells. Genetic or pharmacological inhibition of NCLX, another mitochondrial calcium efflux channel, also leads to senolysis, while inhibition of the main Ca2+ influx channel, MCU, prevents senolysis induced by CypD inhibition. We conclude that senescent cells are highly vulnerable to elevated mitochondrial Ca2+ ions, and that transient CypD/mPTP opening is a critical adaptation mechanism for the survival of senescent cells.
MP was supported by the European Union’s Horizon 2021 research and innovation programme under the Marie Sklodowska-Curie grant agreement (HORIZON-MSCA-2021-PF-01) and the Barcelona Institute of Science and Technology (BIST). VLP was recipient of a predoctoral contract from Spanish Ministry of Education (FPU-18/05917). JB, NH, and JM work was funded by the Asociación Española Contra el Cancer (AECC; PRYCO211023SERR) and by the Instituto de Salud Carlos III (CP19/00170). SR was funded by the NIH Intramural Research Program. MK was funded by the Barcelona Institute of Science and technology (BIST) and Asociación Española Contra el Cáncer (AECC; POSTD18020SERR) and supported by the European Molecular Biology Organization (EMBO). Work in the laboratory of MS was funded by the IRB and “laCaixa” Foundation, by a Coordinated-AECC grant (PRYCO211023SERR), and by Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement of Catalonia (Grup de Recerca consolidat 2017 SGR 282).
Article
Versió publicada
Anglès
Malalties - Tractament; Mitocondris; Cèl·lules - Envelliment; ANATOMY::Cells::Cellular Structures::Intracellular Space::Cytoplasm::Cytoplasmic Structures::Organelles::Mitochondria; CHEMICALS AND DRUGS::Enzymes and Coenzymes::Enzymes::Isomerases::cis-trans-Isomerases::Peptidylprolyl Isomerase::Immunophilins::Cyclophilins; PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cellular Senescence; DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease; Other subheadings::Other subheadings::Other subheadings::/drug therapy; ANATOMÍA::células::estructuras celulares::espacio intracelular::citoplasma::estructuras citoplasmáticas::orgánulos::mitocondrias; COMPUESTOS QUÍMICOS Y DROGAS::enzimas y coenzimas::enzimas::isomerasas::cis-trans-isomerasas::peptidilprolil isomerasa::inmunofilinas::ciclofilinas; FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::senescencia celular; ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::enfermedad; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
EMBO Press
The EMBO Journal;43(23)
https://doi.org/10.1038/s44318-024-00259-2
info:eu-repo/grantAgreement/ES/PE2017-2020/CP19%2F00170
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3412]
Articles científics - VHIR [1655]